Literature DB >> 8669531

Nodal nevi and cutaneous melanomas.

K F Carson1, D R Wen, P X Li, A M Lana, C Bailly, D L Morton, A J Cochran.   

Abstract

Nevocytes in melanoma-draining lymph nodes can be mistaken for melanoma metastases and may possibly transform to melanoma. During the development of a new technique for managing high-risk primary melanomas, selective lymph node dissection, we examined 4,821 nodes from 208 melanoma patients by light microscopy and immunohistochemistry. Nodal nevi were identified in 49 of 226 lymphadenectomy specimens (22%), a frequency considerably higher than previously recorded (5-6%). Nevi occurred in 57 of 4,821 nodes (1.2%), in 84% of patients in one node, in 13% of patients in two nodes, and in 3% of patients in three nodes. Nevocytes were detected in hematoxylin and eosin-stained sections in 38 of 49 cases (78%) and exclusively by immunocytochemistry with an antibody to S-100 protein in 11 of 49 (22%). Nevi were in the peripheral capsule in 93% of cases and in internal trabecula in the remaining 7%. Nevocytes surrounded a small vessel in 33% of cases. Nevi were more frequent in axillary (37 of 140, 26%) and cervical nodes (seven of 40, 18%) than in inguinal nodes (five of 46, 11%). Nevi were more frequent in sentinel nodes, the first nodes on the lymphatics draining a primary melanoma (11 of 284, 3.9%), than in nonsentinel nodes (46 of 4,537, 1.01%; p < 0.0008). One of 1,071 nodes from 50 patients with breast cancer (0.1%) and none of 521 nodes from 50 patients with pelvic cancer contained nevocytes. That nodal nevi are selectively present in melanoma patients raises the possibility of their origin from nodal melanocytes influenced by tumor products. Alternatively, the association may indicate that the nevocytes of cutaneous nevi can be disrupted and displaced by the growth of an adjacent melanoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8669531     DOI: 10.1097/00000478-199607000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  25 in total

1.  Quantification of melanoma mRNA markers in sentinel nodes: pre-clinical evaluation of a single-step real-time reverse transcriptase-polymerase chain reaction assay.

Authors:  Helene N Abrahamsen; Ebba Nexo; Torben Steiniche; Stephen J Hamilton-Dutoit; Boe S Sorensen
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

2.  Intracapsular melanoma: a new pitfall for sentinel lymph node biopsy.

Authors:  B G Howell; J E Lipa; D M Ghazarian
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.

Authors:  Annette H Chakera; Birger Hesse; Zeynep Burak; James R Ballinger; Allan Britten; Corrado Caracò; Alistair J Cochran; Martin G Cook; Krzysztof T Drzewiecki; Richard Essner; Einat Even-Sapir; Alexander M M Eggermont; Tanja Gmeiner Stopar; Christian Ingvar; Martin C Mihm; Stanley W McCarthy; Nicola Mozzillo; Omgo E Nieweg; Richard A Scolyer; Hans Starz; John F Thompson; Giuseppe Trifirò; Giuseppe Viale; Sergi Vidal-Sicart; Roger Uren; Wendy Waddington; Arturo Chiti; Alain Spatz; Alessandro Testori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10       Impact factor: 9.236

4.  Genetic investigation of nodal melanocytic nevi in cases of giant congenital melanocytic nevus.

Authors:  Y Cao; X Yang; Y-M Lai; L Jia; X-T Diao; Q Zhuang; D-M Lin
Journal:  Histol Histopathol       Date:  2020-07-30       Impact factor: 2.303

5.  Sentinel lymph node: detection of micrometastases of melanoma in a molecular study.

Authors:  Valeria C Denninghoff; Andrea G Kahn; Jorge Falco; Hector P Curutchet; Boris Elsner
Journal:  Mol Diagn       Date:  2004

6.  Polymerase chain reaction and immunohistochemistry frequently detect occult melanoma cells in regional lymph nodes of melanoma patients.

Authors:  N Hatta; M Takata; K Takehara; K Ohara
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

7.  Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma.

Authors:  Scott R Dalton; Pedram Gerami; Nicholas A Kolaitis; Susan Charzan; Rob Werling; Philip E LeBoit; Boris C Bastian
Journal:  Am J Surg Pathol       Date:  2010-02       Impact factor: 6.394

Review 8.  Melanoma in pediatric, adolescent, and young adult patients.

Authors:  John M Kirkwood; Drazen M Jukic; Bruce J Averbook; Leonard S Sender
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929

9.  Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus.

Authors:  Daniela Mihic-Probst; Parvin Saremaslani; Paul Komminoth; Philipp U Heitz
Journal:  Virchows Arch       Date:  2003-10-24       Impact factor: 4.064

Review 10.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.